Skip to main content
. Author manuscript; available in PMC: 2011 Sep 28.
Published in final edited form as: Clin Cancer Res. 2009 Feb 15;15(4):1126–1132. doi: 10.1158/1078-0432.CCR-08-0144

Table 1.

Agents targeting anti-apoptotic Bcl-2 family proteins

Agents Target proteins Sponsor Stage
Apogossypol Bcl-2, Bcl-XL, Mcl-1 Burnham (NCI) Preclinical
HA-14 Bcl-2 Maybridge Chem Preclinical
Antimycin A Bcl-2, Bcl-XL U of Washington Preclinical
BH3Is Bcl-XL Harvard U Preclinical
Oblimersen sodium Bcl-2 Genta Phase III
Gossypol (AT-101) Bcl-2, Bcl-XL, Bcl-w, Mcl-1 Ascenta (NCI) Phase I/II
ABT-737 (ABT-263) Bcl-2, Bcl-XL, Bcl-w Abbott Phase I
GX15-070 Bcl-2, Bcl-XL, Bcl-w, Mcl-1 Gemin X Phase I

Abbreviations: BH3Is, BH3 inhibitors; NCI, National Cancer Institute; Maybridge Chem, Maybridge Chemical Co. Ltd.; U, University.